Allos Therapeutics to Report First Quarter 2010 Financial Results on May 5, 2010
21 Abril 2010 - 9:00AM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics, today announced that Company
management will provide a corporate update and review of the first
quarter 2010 financial results via webcast and conference call on
Wednesday, May 5, 2010, at 4:30 p.m. ET.
To access the live audio webcast or the subsequent archived
recording, visit the “Investors - Presentations and Events” section
of the Company’s website at www.allos.com. Alternatively, callers
may participate in the conference call by dialing 1-877-941-0844
(domestic) or 480-629-9644 (international). Participants should
reference the Allos Therapeutics conference call. Webcast and
telephone replays of the conference call will be available
approximately two hours after the completion of the call through
May 19, 2010. To access the replay, callers should dial
1-800-406-7325 (domestic) or 303-590-3030 (international) and use
passcode 4285655#.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq:ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics. Allos is currently focused on
the development and commercialization of FOLOTYN® (pralatrexate
injection), a folate analogue metabolic inhibitor. FOLOTYN is the
first and only drug approved in the U.S. for the treatment of
patients with relapsed or refractory peripheral T-cell lymphoma.
Allos is also developing FOLOTYN in other potential indications.
Allos retains exclusive worldwide rights to FOLOTYN for all
indications. Allos is headquartered in Westminster, Colo. For
additional information, please visit www.allos.com.
Safe Harbor Statement
The first quarter 2010 financial results press release and
conference call will contain forward-looking statements that
involve significant risks and uncertainties, including those
contained in the "Risk Factors" section of the Company's Form 10-K
for the year ended December 31, 2009 and in the Company's other
periodic reports and filings with the Securities and Exchange
Commission. Allos is providing the information contained in the
press release and conference call as of the date of the release and
does not undertake any obligation to update any forward-looking
statements as a result of new information, future events or
otherwise. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in the press
release or the conference call. No forward-looking statement can be
guaranteed and actual events and results may differ materially from
those projected.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Allos Therapeutics, Inc.